Cell therapy research publication RegMedNet has just posted HemaCare’s latest article on how to use apheresis and cell collection techniques to optimize starting material quality. [1]
An Expansive Donor Network Helps Guarantee Consistent Quality
Apheresis donor material is intrinsically variable, yet a successful cell therapy product must have consistent efficacy across a wide range of patients. How do we reconcile these realities? As a large-scale apheresis supplier, HemaCare understands that quality raw materials are a matter of careful planning and expertise. Inter-donor variability can impact critical parameters including cell collection volume, cell subtype composition and cell proliferation potential. [2] Each of these parameters impact apheresis unit potency, and can impact resource use and manufacturing efficiency.